-- Scott Roberts
FRIDAY, April 29 (HealthDay News) -- Zytiga (abiraterone
acetate), used in combination with the steroid prednisone, has been
approved to treat advanced prostate cancer, the U.S. Food and Drug
Administration said in a news release.
The growth of cancerous prostate tumors is fueled by the male
hormone testosterone, and the new drug combination blocks a protein
that plays a key role in body's production of testosterone, the
Zytiga was evaluated in clinical studies involving 1,195 men
with advanced prostate cancer whose tumors continued to grow
despite chemotherapy. Men who received the Zytiga/prednisone
combination lived an average of 14.8 months, compared with 10.9
months among men who took a placebo, the FDA said.
The most common adverse reactions to the drug combination
included joint discomfort, low blood potassium, fluid retention,
muscle discomfort, hot flashes, diarrhea, urinary tract infection,
cough, high blood pressure, heartbeat abnormalities, increased
urinary frequency, upset stomach and upper respiratory
Zytiga is produced by Centocor Ortho Biotech, based in Horsham,
To learn more about prostate cancer, visit the U.S.
National Cancer Institute.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.